<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35531876</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2165-5987</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Bioengineered</Title>
          <ISOAbbreviation>Bioengineered</ISOAbbreviation>
        </Journal>
        <ArticleTitle>MicroRNA-146 attenuates lipopolysaccharide induced ovarian dysfunction by inhibiting the TLR4/NF- κB signaling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>11611</StartPage>
          <EndPage>11623</EndPage>
          <MedlinePgn>11611-11623</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/21655979.2022.2070584</ELocationID>
        <Abstract>
          <AbstractText>Premature ovarian insufficiency (POI) is a disease that seriously affects women's reproductive function and even leads to lifelong infertility. Little is known about the mechanism of lipopolysaccharide (LPS)-induced ovarian dysfunction. Thus, we aimed to identify the role of the up-regulation of microRNA (miRNA)-146 expression offered protection against ovarian dysfunction by inhibiting the toll-like receptor (TLR) 4, TLR4/phosphorylated (p)-nuclear factor (NF)-κB signaling pathway and inflammatory cytokine tumor necrosis factor (TNF)-a and Interleukin (IL)-6. In an in vivo study, we established an LPS-induced ovarian dysfunction mouse model. The mouse ovarian granulosa cells were transfected with miR-146 mimic or negative controls or inhibitor and then treated with LPS. Therefore, cell viability, cells apoptosis, IL-6 and TNF-a, TLR4, NF- κB were assessed, respectively. These results demonstrated that the up-regulation of miRNA-146 expression may protect against LPS-induced ovarian dysfunction and markedly increased the cell viability, and significantly reduced the ovarian granulosa cells apoptotic rate, and down-regulated IL-6 and TNF-a expression. In addition, miRNA-146 exerted protective ovarian functions might be via inhibiting TLR4/NF-κB signaling pathway. In summary, we reveal the up-regulation of miRNA-146 expression mitigated ovarian dysfunction by negatively regulating expression of the IL-6 and TNF-a, which may shed light on the potential molecular mechanisms of overexpression of miRNA-146 may reversed the ovarian dysfunction by inhibiting the TLR4/ NF-κB signaling pathway.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Fengping</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Affiliated Dongguan Maternal and Child Health Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yanhui</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Affiliated Dongguan Maternal and Child Health Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Tang</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Affiliated Dongguan Maternal and Child Health Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Qiulin</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Affiliated Dongguan Maternal and Child Health Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yongmei</LastName>
            <ForeName>Zhang</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Affiliated Dongguan Maternal and Child Health Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Peiqing</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Affiliated Dongguan Maternal and Child Health Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiong</LastName>
            <ForeName>Chuanyin</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Affiliated HuaDu Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Bioengineered</MedlineTA>
        <NlmUniqueID>101581063</NlmUniqueID>
        <ISSNLinking>2165-5979</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C542542">MIRN146 microRNA, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C534190">Mirn146 microRNA, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495345">TLR4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C493487">Tlr4 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016328" MajorTopicYN="Y">NF-kappa B</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010049" MajorTopicYN="Y">Ovarian Diseases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010053" MajorTopicYN="N">Ovary</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051197" MajorTopicYN="Y">Toll-Like Receptor 4</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">apoptosis</Keyword>
        <Keyword MajorTopicYN="N">lipopolysaccharide (LPS)</Keyword>
        <Keyword MajorTopicYN="N">miRNA-146</Keyword>
        <Keyword MajorTopicYN="N">ovarian dysfunction</Keyword>
        <Keyword MajorTopicYN="N">ovarian insufficiency (POI)</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>9</Day>
          <Hour>5</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35531876</ArticleId>
        <ArticleId IdType="doi">10.1080/21655979.2022.2070584</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
